Dara-RVD as first line treatment in transplant-eligible MM
GRIFFIN trial
Background: Revlimid, bortezomib and dexamethasone induction therapy followed by autologous stem cell transplant has been established as the first-line therapy for newly diagnosed multiple myeloma (NDMM). However, this is not a curative regimen. Efforts are still needed to deepen responses and have them translate into improved progression-free survival …
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.